<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405064</url>
  </required_header>
  <id_info>
    <org_study_id>W-771/2349-301</org_study_id>
    <nct_id>NCT03405064</nct_id>
  </id_info>
  <brief_title>Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</brief_title>
  <official_title>A Phase III, Multi-centre, Randomized Study to Compare the Efficacy and Safety of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multi-center, randomized, active-comparator, study in subjects with
      ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1
      and IV subgroup 2. Each subgroup will comprise of two treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects willing to participate in the study and fulfilling all eligibility criteria will
      receive either oral therapy (subgroup 1) or IV therapy (subgroup 2). The investigator can
      initiate treatment with either oral or IV therapy based on clinical judgement i.e subjects
      who require IV therapy (like subjects with severe ABSSSI or where oral administration is not
      feasible).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The non-inferiority of oral levonadifloxacin with oral linezolid in ABSSSI by measuring the Overall Clinical Response at Test of Cure (TOC) visit in modified Intentto-treat (mITT) population in oral treatment subgroups</measure>
    <time_frame>0-14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the non-inferiority of IV levonadifloxacin with IV linezolid in ABSSSI measuring the Overall Clinical Response at Test of Cure (TOC) visit in modified Intentto-treat (mITT) population in IV treatment subgroups</measure>
    <time_frame>0-14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of oral and IV levonadifloxacin based on adverse events reported, vital signs and physical examination findings, clinical laboratory evaluation, and ECG collected during the study.</measure>
    <time_frame>0-14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>levonadifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral linezolid (600 mg BID) or IV linezolid (600 mg BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Levonadiflixacin/Linezolid Tablet</intervention_name>
    <description>oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)</description>
    <arm_group_label>levonadifloxacin</arm_group_label>
    <arm_group_label>linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Levonadiflixacin/Linezolid Infusion</intervention_name>
    <description>IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)</description>
    <arm_group_label>levonadifloxacin</arm_group_label>
    <arm_group_label>linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be willing to participate in the study and provide a written informed
             consent

          -  Subjects with ABSSSI characterized by any of the following infection types:

               1. Cellulitis/erysipelas: diffuse skin infection characterized by spreading areas of
                  redness, edema, and/or induration

               2. Wound infection: An infection characterized by purulent drainage from a wound
                  with surrounding redness, edema, and/or induration

               3. Major cutaneous abscess: An infection characterized by a collection of pus within
                  the dermis or deeper that is accompanied by redness, edema, and/or induration

          -  Subjects with lesion size area of at-least 75 cm2. Lesion size will be measured by the
             area of redness, edema, or induration

          -  Subjects with suspected and/or documented evidence of Gram-positive infection

        Exclusion Criteria:

          -  1. ABSSSI meeting any of the following criteria:

               1. Severely impaired arterial blood supply (such that the likelihood of amputation
                  of the infected anatomical site is likely)

               2. ABSSSI expected to require more than 10 days of antimicrobial therapy as per the
                  discretion of the Investigator

               3. Subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene

               4. ABSSSI requiring surgical intervention (except surgical incision and drainage for
                  abscess) 2. Subjects who have received prior antibiotic therapy within past 24
                  hours for the treatment of current episode of ABSSSI. Following are the
                  exceptions to this criteria:

               1. Subjects who received a single dose of a short-acting antibacterial drug within
                  24 hours of enrolment

               2. Subjects with evidence of clinical progression of ABSSSI while on antibacterial
                  drug therapy after at-least 48 hours

               3. Subjects who received an antibacterial drug for surgical prophylaxis and
                  subsequently develop ABSSSI 3. Subjects with current history or diagnosis of HIV,
                  positive test result for hepatitis B surface antigen (HBsAg) or Hepatitis C virus
                  (HCV) 4. Subjects with any clinically significant abnormalities in pulmonary,
                  gastrointestinal, endocrine, hepatic or renal systems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Chugh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Chugh, MD</last_name>
    <phone>+91 22 7159</phone>
    <phone_ext>6833</phone_ext>
    <email>rchugh@wockhardt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashima Bhatia, MD</last_name>
    <phone>+91 22 7159</phone>
    <phone_ext>6830</phone_ext>
    <email>abhatia@wockhardt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GMERS Medical College &amp; General Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390021</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhavin Patel, MD</last_name>
      <phone>91-9898216643</phone>
      <email>gmers.trials@spearsmind.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mysore Medical College and Research Institute</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohan Kakola, MD</last_name>
      <phone>91-9890318105</phone>
      <email>dryunus29@rediffmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Govt. Medical College</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>Kozhikode,</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kozhikode, , MD</last_name>
      <phone>91-8589951229</phone>
      <email>researchatcmc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TNMC &amp; BYL Nair Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayashri Pandya, MD</last_name>
      <phone>91-9833774575</phone>
      <email>smruti63@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>G.S. Medical College &amp; KEM Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind Prabhakar More, MD</last_name>
      <phone>91-9820541126</phone>
      <email>drmilindpmore@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>B.J. Medical College and Sassoon General Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001,</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lata Bhoir, MD</last_name>
      <phone>91-9764132444</phone>
      <email>drlatabhoir@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oyster &amp; Pearl Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shekhar Takale, MD</last_name>
      <phone>+91 9960444711</phone>
      <email>drshekhar7@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Takale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KEM Hospital Research Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bharat Kalambe, MD</last_name>
      <phone>9822174858</phone>
      <email>bkalambe@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noble Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umesh Paprunia, MD</last_name>
      <phone>91-9860172720</phone>
      <email>umeshpaprunia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Datta Meghe Institute of Medical Sciences (Deemed University) Jawaharlal Nehru Medical College</name>
      <address>
        <city>Wardha</city>
        <state>Maharashtra</state>
        <zip>442004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandrashekhar Mahakalkar, MD</last_name>
      <phone>91-9822369277</phone>
      <email>cmahakalkar@rediffmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital &amp; Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SandeepKumar Gupta, MD</last_name>
      <phone>8400388966</phone>
      <email>sandeepkumar.gupta@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>SandeepKumar Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajanta Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>2260055</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Khanna, MD</last_name>
      <phone>+91 9335242509</phone>
      <email>dr_khanna@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Khanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Om Surgical &amp; Maternity Home</name>
      <address>
        <city>Varanasi</city>
        <state>Uttar Pradesh</state>
        <zip>22100</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Srivastava, MD</last_name>
      <phone>91-9415226817</phone>
      <email>omresearchcenter@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

